BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding BioAtla, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 76 | 87 | +11 |
| Shares | 21.2M | 25.4M | +4.19M (+19.8%) |
| Value | $897.0M | $746.4M | −$150.6M (−16.8%) |
New holders (22)
Institutions that held BioAtla, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (11)
Institutions that held BioAtla, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Citadel Advisors LLC | 152,999 | $6.48M |
| FIL Ltd | 27,338 | $1.16M |
| Squarepoint Ops LLC | 7,920 | $336.0K |
| Oppenheimer & Co Inc | 5,833 | $247.0K |
| United Capital Financial Advisers, LLC | 5,432 | $230.0K |
| Pachira Investments Inc. | 5,100 | $216.0K |
| Allstate Corp | 5,031 | $213.0K |
| Frontier Wealth Management LLC | 4,994 | $212.0K |
| Voya Investment Management LLC | 4,791 | $203.0K |
| Lindbrook Capital, LLC | 300 | $13.0K |
| Captrust Financial Advisors | 92 | $4.00K |